OrbiMed Advisors ANRO Position
Active6-Fund ConvergenceOrbiMed Advisors trimmed their position in Alto Neuroscience, Inc. (ANRO) in Q4 2025, holding $2.2M worth of shares across 125,000 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
ANRO is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ALTO-100 in 137 days (Aug 31, 2026), making the timing of OrbiMed's position particularly relevant.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Full company profile →Short Interest
7.8%
6.5 days to cover
OrbiMed Advisors ANRO Position History
Frequently Asked Questions
Does OrbiMed Advisors own ANRO?
Yes. As of Q4 2025, OrbiMed Advisors holds 125,000 shares of Alto Neuroscience, Inc. (ANRO) valued at $2.2M. This data comes from their SEC 13F filing.
How many hedge funds own ANRO?
6 specialist biotech hedge funds currently hold ANRO, including Commodore Capital, Perceptive Advisors, RA Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy ANRO?
OrbiMed Advisors's position in ANRO was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's ANRO position increasing or decreasing?
OrbiMed Advisors trimmed their ANRO position in the most recent quarter, reducing by 125,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ANROCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →